Extrawell Pharmaceutical Holdings Limited (0858.HK)
HKD 0.05
(2.04%)
HKD 0.05
(2.04%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -129.51 Million HKD | 130.17% |
| 2022 | 159.05 Million HKD | 74.67% |
| 2021 | 157.84 Million HKD | -1009.81% |
| 2020 | -97.47 Million HKD | 110.77% |
| 2019 | 101.14 Million HKD | 6.04% |
| 2018 | 77.43 Million HKD | 1.42% |
| 2017 | 42.44 Million HKD | -27.08% |
| 2016 | 31.29 Million HKD | -225.69% |
| 2015 | 6.78 Million HKD | -57.73% |
| 2014 | -42.17 Million HKD | 355.32% |
| 2013 | 42.71 Million HKD | -147.87% |
| 2012 | 12.98 Million HKD | 4.62% |
| 2011 | 20.92 Million HKD | -28.33% |
| 2010 | 8.94 Million HKD | -27.11% |
| 2009 | 18.5 Million HKD | 21.75% |
| 2008 | 14.14 Million HKD | 153.13% |
| 2007 | 7.79 Million HKD | 82.18% |
| 2006 | 4.27 Million HKD | -51.28% |
| 2005 | 13.42 Million HKD | 112.62% |
| 2004 | -79.41 Million HKD | -118.58% |
| 2003 | -31.82 Million HKD | -159.91% |
| 2002 | 53.11 Million HKD | 15.51% |
| 2001 | 51.52 Million HKD | 94.7% |
| 2000 | 23.61 Million HKD | 69.05% |
| 1999 | 13.97 Million HKD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 FY | - HKD | 130.17% |
| 2023 Q2 | 1.12 Million HKD | 0.0% |
| 2023 Q4 | 395 Thousand HKD | 0.0% |
| 2022 Q4 | 1.38 Million HKD | 0.0% |
| 2022 FY | - HKD | 74.67% |
| 2022 Q2 | -3.87 Million HKD | 0.0% |
| 2021 FY | - HKD | -1009.81% |
| 2021 Q2 | 702 Thousand HKD | 0.0% |
| 2021 Q4 | -10.52 Million HKD | 0.0% |
| 2020 Q4 | 797 Thousand HKD | 0.0% |
| 2020 FY | - HKD | 110.77% |
| 2020 Q2 | 253 Thousand HKD | 0.0% |
| 2019 FY | - HKD | 6.04% |
| 2019 Q2 | -656 Thousand HKD | 0.0% |
| 2019 Q4 | -9.37 Million HKD | 0.0% |
| 2018 FY | - HKD | 1.42% |
| 2018 Q4 | -6.76 Million HKD | 0.0% |
| 2018 Q2 | -3.91 Million HKD | 0.0% |
| 2017 Q2 | -4.51 Million HKD | 0.0% |
| 2017 Q4 | -6.31 Million HKD | 0.0% |
| 2017 FY | - HKD | -27.08% |
| 2016 Q4 | -8.46 Million HKD | 0.0% |
| 2016 FY | - HKD | -225.69% |
| 2016 Q2 | -57 Thousand HKD | 0.0% |
| 2015 Q1 | 143.87 Million HKD | 0.0% |
| 2015 Q4 | 663 Thousand HKD | 0.0% |
| 2015 Q2 | 6.11 Million HKD | -95.75% |
| 2015 FY | - HKD | -57.73% |
| 2014 Q2 | -4 Million HKD | -140.0% |
| 2014 Q1 | 10 Million HKD | 0.0% |
| 2014 Q3 | 143.87 Million HKD | 3696.08% |
| 2014 Q4 | 143.87 Million HKD | 0.0% |
| 2014 FY | - HKD | 355.32% |
| 2013 FY | - HKD | -147.87% |
| 2013 Q4 | 10 Million HKD | 0.0% |
| 2013 Q3 | 10 Million HKD | 69.77% |
| 2013 Q2 | 5.89 Million HKD | 60.64% |
| 2013 Q1 | 3.66 Million HKD | 26.34% |
| 2012 Q2 | 6.35 Million HKD | 0.0% |
| 2012 Q1 | 6.35 Million HKD | 0.0% |
| 2012 Q4 | 2.9 Million HKD | -20.85% |
| 2012 FY | - HKD | 4.62% |
| 2012 Q3 | 3.66 Million HKD | -42.25% |
| 2011 FY | - HKD | -28.33% |
| 2011 Q1 | 4.11 Million HKD | 0.0% |
| 2011 Q2 | 4.11 Million HKD | 0.0% |
| 2011 Q3 | 6.35 Million HKD | 54.36% |
| 2011 Q4 | 6.35 Million HKD | 0.0% |
| 2010 FY | - HKD | -27.11% |
| 2010 Q1 | 4.38 Million HKD | 0.0% |
| 2010 Q4 | 4.11 Million HKD | 0.0% |
| 2010 Q3 | 4.11 Million HKD | -6.25% |
| 2010 Q2 | 4.38 Million HKD | 0.0% |
| 2009 Q3 | 4.38 Million HKD | 42.86% |
| 2009 Q4 | 4.38 Million HKD | 0.0% |
| 2009 FY | - HKD | 21.75% |
| 2009 Q1 | 3.07 Million HKD | 0.0% |
| 2009 Q2 | 3.07 Million HKD | 0.0% |
| 2008 FY | - HKD | 153.13% |
| 2008 Q1 | 1.9 Million HKD | 0.0% |
| 2008 Q4 | 3.07 Million HKD | 0.0% |
| 2008 Q2 | 1.9 Million HKD | 0.0% |
| 2008 Q3 | 3.07 Million HKD | 61.12% |
| 2007 Q1 | 3.64 Million HKD | 0.0% |
| 2007 FY | - HKD | 82.18% |
| 2007 Q4 | 1.9 Million HKD | 0.0% |
| 2007 Q3 | 1.9 Million HKD | -47.73% |
| 2007 Q2 | 3.64 Million HKD | 0.0% |
| 2006 Q4 | 3.64 Million HKD | 0.0% |
| 2006 FY | - HKD | -51.28% |
| 2006 Q2 | 3.13 Million HKD | 0.0% |
| 2006 Q3 | 3.64 Million HKD | 16.56% |
| 2006 Q1 | 3.13 Million HKD | 0.0% |
| 2005 Q1 | -15.09 Million HKD | 0.0% |
| 2005 Q2 | -15.09 Million HKD | 0.0% |
| 2005 FY | - HKD | 112.62% |
| 2005 Q3 | 3.13 Million HKD | 120.74% |
| 2005 Q4 | 3.13 Million HKD | 0.0% |
| 2004 Q4 | -15.09 Million HKD | 0.0% |
| 2004 Q1 | 10.08 Million HKD | 0.0% |
| 2004 Q2 | 10.08 Million HKD | 0.0% |
| 2004 Q3 | -15.09 Million HKD | -249.74% |
| 2004 FY | - HKD | -118.58% |
| 2003 Q1 | 16.16 Million HKD | 0.0% |
| 2003 FY | - HKD | -159.91% |
| 2003 Q4 | 10.08 Million HKD | 0.0% |
| 2003 Q3 | 10.08 Million HKD | -37.65% |
| 2003 Q2 | 16.16 Million HKD | 0.0% |
| 2002 FY | - HKD | 15.51% |
| 2002 Q4 | 16.16 Million HKD | 0.0% |
| 2002 Q3 | 16.16 Million HKD | 40.95% |
| 2002 Q2 | 11.47 Million HKD | 0.0% |
| 2002 Q1 | 11.47 Million HKD | 0.0% |
| 2001 FY | - HKD | 94.7% |
| 2001 Q4 | 11.47 Million HKD | 0.0% |
| 2001 Q3 | 11.47 Million HKD | 92.36% |
| 2001 Q2 | 5.96 Million HKD | 0.0% |
| 2001 Q1 | 5.96 Million HKD | 0.0% |
| 2000 Q4 | 5.96 Million HKD | 0.0% |
| 2000 Q3 | 5.96 Million HKD | 48.79% |
| 2000 Q2 | 4 Million HKD | 0.0% |
| 2000 Q1 | 4 Million HKD | 0.0% |
| 2000 FY | - HKD | 69.05% |
| 1999 Q3 | 4 Million HKD | 0.0% |
| 1999 Q4 | 4 Million HKD | 0.0% |
| 1999 FY | - HKD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Pak Fah Yeow International Limited | 150.4 Million HKD | 186.117% |
| Grand Pharmaceutical Group Limited | 2.96 Billion HKD | 104.366% |
| Wai Yuen Tong Medicine Holdings Limited | 113.79 Million HKD | 213.816% |
| Qianhai Health Holdings Limited | -50.22 Million HKD | -157.859% |
| Lee's Pharmaceutical Holdings Limited | 109.82 Million HKD | 217.938% |
| Essex Bio-Technology Limited | 418.37 Million HKD | 130.958% |
| Tongfang Kontafarma Holdings Limited | 76.63 Million HKD | 269.013% |
| PuraPharm Corporation Limited | -26.16 Million HKD | -394.937% |
| SSY Group Limited | 2.11 Billion HKD | 106.125% |
| JBM (Healthcare) Limited | 204.39 Million HKD | 163.369% |
| Jacobson Pharma Corporation Limited | 429.92 Million HKD | 130.126% |
| China Resources Pharmaceutical Group Limited | 15.43 Billion HKD | 100.839% |